Zal Bilimoria discusses the varying paths to liquidity for companies solving fundamental human problems, highlighting the different timelines for therapeutics companies versus those in the biology sphere. He also mentions the importance of early relationships with pharma companies and the potential for rapid value creation in certain sectors.
